Even the Pandemic Hasn ’t Made Public-Health Icon Paul Farmer Lose Hope
“Am I allowed to be a normal human and say, ‘How are you?'” asks Dr. Paul Farmer as soon as our Zoom call connects.
It’s an apt introduction for a man who became a living legend in the global health world mostly by being a normal human who does extraordinary things–starting with co-founding the Boston-based nonprofit organization Partners in Health (PIH) in 1987, before graduating from Harvard Medical School. Since then, PIH and its global staff of 18,000 have helped strengthen health systems in the “clinical deserts” of Haiti, Rwanda, Peru, Russia and numerous other countries. PIH...
Source: TIME: Health - December 3, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Magazine Public Health Second click Source Type: news
Cutting UK overseas aid could harm the fight against future pandemics | Matthew Baylis and Fiona Tomley
In our age of emerging pathogens, funding for global research into zoonotic diseases such as Covid-19, Ebola and Sars is vitalCoronavirus – latest updatesSee all our coronavirus coverageThis year, we ’ve seen how a previously unknown animal virus can spill over into the human population in one country, pass rapidly between people, and spread across the world in days. With nearly1.5m reported deaths from Covid-19, the virus is a startling indication of how the health of the world ’s human population is inseparable from animals and the environment that we share with them.Treating health in a way that recognises these i...
Source: Guardian Unlimited Science - December 2, 2020 Category: Science Authors: Matthew Baylis and Fiona Tomley Tags: Vaccines and immunisation Coronavirus Infectious diseases Microbiology Science Health World news Society Medical research Ebola Sars Aid UK news Source Type: news
Janssen's Two-Dose Ebola Vaccine Appears Safe, Immunogenic in HIV-Infected Patients Janssen's Two-Dose Ebola Vaccine Appears Safe, Immunogenic in HIV-Infected Patients
Janssen ' s two-dose Ebola vaccine appears to be safe for HIV-infected patients and provokes an immune response, although one that initially is not as strong as in HIV-negative patients, according to new research.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 2, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Japan Should Lead Charge for Equitable Access to COVID-19 Vaccines
Credit: United NationsBy Cecilia RussellJOHANNESBURG, South Africa, Nov 20 2020 (IPS) Japan should step up and play a role as a global facilitator for equitable access to COVID-19 vaccines, Dr Daisaku Higashi said at a recent Japan Parliamentarians Federation for Population (JPFP) study meeting.
The country should use the credibility developed in the post-Second World War era as a country with expertise in peacebuilding to ensure that developing countries are included in the vaccines’ rollout.
Higashi, a renowned commentator from Sophia University, warned that only an international effort could solve the problems caused...
Source: IPS Inter Press Service - Health - November 20, 2020 Category: International Medicine & Public Health Authors: Cecilia Russell Tags: Aid Asia-Pacific Development & Aid Economy & Trade Featured Global Headlines Health Humanitarian Emergencies TerraViva United Nations Asian Population and Development Association (APDA) Source Type: news
Third Covid-19 candidate vaccine developed by Janssen Pharmaceutical Companies will be tested in clinical trials involving patients in the UK
Phase 3 placebo controlled RCT will involve 30,000 patients and assess a two dose regimen of the vaccine 57 days apart, using the same human adenovirus that provided the vector for Janssen ' s Ebola virus vaccine. A trial of a single dose by Janssen is already underway in the US. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 18, 2020 Category: Consumer Health News Source Type: news
Covid: 6,000 UK volunteers to be injected with vaccine in phase 3 trial
Third vaccine to undergo large-scale clinical testing in Britain has been modelled on Ebola jabCoronavirus – latest updatesSee all our coronavirus coverageSix thousand British volunteers are to be injected with an experimental Covid vaccine modelled on an Ebola jab.It is the third Covid vaccine to enter large-scale clinical trials in the UK. Pursuing multiple candidates is essential to guarantee UK supply and ensure that most effective vaccine is identified, researchers stressed.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 16, 2020 Category: Science Authors: Linda Geddes Tags: Coronavirus Vaccines and immunisation Health Infectious diseases Medical research UK news Alok Sharma Science Source Type: news
Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate
November 15, 2020 -- The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enroll and vaccinate study participants. ENSEMBLE is proceeding to enroll up to 60,000 participants worldwide.In addition to the single-dose regimen ENSEMBLE study, Janssen has now initiated the two-dose regimen ENSEMBLE 2 trial. ENSEMBLE 2 is a complementary, planned, pivotal, large-scale, multi-country Phase 3 trial that will study the safety and efficacy of a two-dose ...
Source: Johnson and Johnson - November 16, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Why You May Not Be Able to Get Pfizer ’s Frontrunner COVID-19 Vaccine
The freezer in your kitchen likely gets down to temperatures around -20° C (-4° F). “That keeps your ice cream cold, but it doesn’t turn your ice cream into an impenetrable block of ice,” says Paula Cannon, an associate professor of molecular microbiology and immunology at the University of Southern California’s Keck School of Medicine.
Pfizer’s promising COVID-19 vaccine, by contrast, must be stored at about -70° C (-94° F)—a temperature cold enough to harden ice cream into a spoon-breaking block of ice, and that only specialized freezers can produce.
Those cold storage ...
Source: TIME: Health - November 13, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news
COMMENTARY: The Sinatra Doctrine Confronts a Global Consensus
A photo-collage. Credit: Peter Costantini.By Peter CostantiniSEATTLE, Oct 23 2020 (IPS) By late September, the COVID-19 pandemic in the United States had claimed 200,000 lives. That’s equivalent to a slightly higher toll than the 418,500 United States deaths in World War II, adjusted for relative population and duration. [See note below.]
With four percent of the world’s population, the U.S. has suffered 20 percent of global COVID-19 deaths.
Tragically, most of these deaths need never have happened. They were caused primarily by the public-health equivalent of friendly fire: massive malpractice and deception by the Don...
Source: IPS Inter Press Service - Health - October 23, 2020 Category: International Medicine & Public Health Authors: Peter Costantini Tags: Global Geopolitics Global Governance Headlines Health TerraViva United Nations Source Type: news
What Developing Countries Can Teach Us About How To Respond To a Pandemic
This article is republished from The Conversation under a Creative Commons license. Read the original article.
The post What Developing Countries Can Teach Us About How To Respond To a Pandemic appeared first on Inter Press Service. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - October 16, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health TerraViva United Nations Source Type: news
Heidi Larson Knows How to Build Trust in Vaccines
For the founder of the Vaccine Confidence Project, squashing viral rumors means building trust — and avoiding the term “anti-vaxxer.” (Source: NYT Health)
Source: NYT Health - October 13, 2020 Category: Consumer Health News Authors: Jenny Anderson Tags: your-feed-science Coronavirus Risks and Safety Concerns Vaccination and Immunization Coronavirus (2019-nCoV) Rumors and Misinformation Polls and Public Opinion Social Media Computers and the Internet Mumps Measles Epidemics Ebola Vir Source Type: news
Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen ’s COVID-19 Vaccine Candidate
New Brunswick, N.J., October 8, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorization from regulators. The EU Member States also have the option to secure up to 200 million additional doses.“The COVID-19 pandemic continues to threaten communities worldwide and we have a responsibility to ensure access to our C...
Source: Johnson and Johnson - October 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Stop a Pandemic Without Water? Health Workers across the World Need WASH
This article was originally published by the Frontline Health Workers coalition on September 30, 2020.Read it here. (Source: IntraHealth International)
Source: IntraHealth International - September 30, 2020 Category: International Medicine & Public Health Authors: kseaton Tags: COVID-19 Global health security Source Type: news
J & J ’s COVID-19 Vaccine Will Enter Phase 3 Testing, the Fourth To Reach That Stage
Johnson & Johnson announced today (Sept. 23) that it is launching a large-scale Phase 3 test of its COVID-19 vaccine candidate, which was developed based on science supported by the National Institutes of Health. The vaccine, being tested through the company’s Janssen Pharmaceuticals arm, will be the fourth to enter late stage studies, following candidates from Moderna, Pfizer-BioNTech and AstraZeneca. Unlike those vaccine candidates, which all require two shots, J&J’s vaccine involves a single injection. That means it could require half the number of doses to immunize the same number of people.
J&J...
Source: TIME: Health - September 23, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5"},"comscore":{"clientId"...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news
